logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • Proteasome Inhibitor class drugs

    FiltersReset Filters
    4 results

    • bortezomib

      (Bortezomib)
      Ingenus Pharmaceuticals, LLC
      Usage: Bortezomib for Injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

    • kyprolis

      (carfilzomib)
      Onyx Pharmaceuticals, Inc.
      Usage: Kyprolis is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, specifically those who have undergone one to three lines of therapy. It can be used in combination with agents like lenalidomide or daratumumab, or as a single agent following prior therapies.

    • ninlaro

      (ixazomib)
      Takeda Pharmaceuticals America, Inc.
      Usage: NINLARO is indicated for use in combination with lenalidomide and dexamethasone to treat multiple myeloma in patients who have received at least one prior therapy. It is not recommended for maintenance therapy or in newly diagnosed cases outside clinical trials.

    • velcade

      (bortezomib)
      Takeda Pharmaceuticals America, Inc.
      Usage: VELCADE is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.